Influence of Emotions on Decision-making in Parkinson’s Disease

Overview

Parkinson's disease mainly affects the dopaminergic neurons of the Substancia nigra, which project on the striatum. Neuronal death within this structure leads to a decrease in dopamine levels. Dopamine is a neurotransmitter essential to the proper functioning of the basal ganglia highly involved in the control of voluntary and involuntary movements. It also leads to cognitive and behavioral changes. Among these changes, the investigators will mainly remember the idea of the emergence of difficulties to make the right decisions, for example at the financial, medical …. This disruption would be the result of executive dysfunction. By definition, executive functions allow us to evaluate, plan and organize our actions to achieve a goal.

Full Title of Study: “Influence of Emotions on Decision-making in Parkinson’s Disease”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Other
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 20, 2020

Detailed Description

Some research shows that positive emotional states are associated with greater self-confidence, greater optimism, and better regulation of our decision-making. The goal is to test whether positive emotional induction could improve decision-making in Parkinson's disease. Listening to music would decrease anxiety levels and increase self-esteem levels. Who says Parkinson says dopamine deficiency and so the investigators can think that the investigators can help patients by inducing a positive emotion through musical stimulation. All participants will be subject to emotional induction. They will be divided into two different conditions: either they will be induced in a positive state, or they will be maintained in a neutral state. For this, video clips (positive or neutral) containing music will be presented. Immediately after the presentation of the video, participants will have to perform the Iowa Gambling Task test. This is a sequential task to evaluate decision-making capabilities.

Interventions

  • Other: cognitive examination
    • mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test
  • Other: viewing of video
    • viewing during 5 minutes scale of differential emotions and Positive and Negative Affect Scale
  • Other: Iowa Gambling Task
    • Test of Iowa Gambling Task

Arms, Groups and Cohorts

  • Other: patients with Parkinson’s disease
    • cognitive examination : mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test viewing of video : scale of differential emotions and Positive and Negative Affect Scale Test of Iowa Gambling Task
  • Other: witnesses
    • cognitive examination : mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test viewing of video : scale of differential emotions and Positive and Negative Affect Scale Test of Iowa Gambling Task

Clinical Trial Outcome Measures

Primary Measures

  • net score of Iowa Gambling Task Test
    • Time Frame: day 1
    • calculated by adding the number of cards taken in the right pile and subtracting it from the number of cards chosen in the wrong pile

Participating in This Clinical Trial

Inclusion Criteria for patients :

  • Diagnosis of the disease carried out by a hospital doctor – Stable treatment for two months minimum. – Mini-Mental Parkinson > 26 – Under dopaminergic treatment Exclusion Criteria for patients : – other neurological or psychiatric antecedents – anxio-depressive symptomatology – delusional or psychotic state Inclusion Criteria for witnesses : – matched in age and sex – Vision and hearing normal or successfully corrected – Understand the French language – general level in the test standard Exclusion Criteria for witnesses : – neurological or psychiatric diseases – anxio-depressive symptomatology

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Centre Hospitalier Universitaire de Saint Etienne
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.